Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.